Drug Price Trends for TALTZ

Average Pharmacy Cost for TALTZ

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
TALTZ 80 MG/ML AUTOINJECTOR	00002-1445-01	7347.54475	ML	2026-01-01
TALTZ 80 MG/ML AUTOINJECTOR (2-PACK)	00002-1445-27	7435.87075	ML	2026-01-01
TALTZ 80 MG/ML AUTOINJECTOR	00002-1445-11	7347.54475	ML	2026-01-01

TALTZ Market Analysis and Financial Projection

Last updated: February 14, 2026

Market Overview and Competitive Position

TALTZ (ixekizumab) is a monoclonal antibody developed by Eli Lilly used primarily to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, and other inflammatory conditions. It received FDA approval in 2016 and is marketed globally, with significant penetration in dermatology and rheumatology markets.

Indications and Uses

• Moderate-to-severe plaque psoriasis
• Psoriatic arthritis
• Other autoimmune inflammatory conditions

Market Penetration

• One of the leading IL-17 inhibitors alongside Cosentyx (secukinumab) and Siliq (brodalumab)
• Estimated to hold approximately 15-20% market share among biologics for psoriasis globally (as per IQVIA data, 2022)

Key Competitors

Product	Company	Approval Year	Indications	Estimated Market Share (2022)
TALTZ	Eli Lilly	2016	Psoriasis, PsA	15-20%
Cosentyx	Novartis	2015	Psoriasis, PsA	35-40%
Siliq	BMS	2017	Psoriasis	10-15%
Stelara	J&J	2009	Psoriasis, Crohn’s	15-20%

Market Size and Growth Trends

Global Psoriasis Market

• Valued at approximately $6.7 billion in 2021
• Growing at a CAGR of roughly 8% (2021-2028), driven by increasing prevalence and expanding indications

Revenue Forecasts

• Eli Lilly's TALTZ generated $1.1 billion globally in 2022
• Projected to grow at a CAGR of 7-9% through 2028

Drivers

• Increasing prevalence of psoriasis and psoriatic arthritis worldwide
• Expanded label indications, including axial spondyloarthritis
• Adoption of biosimilars and competitive biologics affects pricing

Price Projections and Economics

Current Pricing

• List Price (US): approximately $5,000 per dose (based on typical dosing schedules)
• Cost per treatment cycle: approximately $25,000–$30,000

Reimbursement and Payer Dynamics

• High reimbursement rates in major markets
• Pricing sensitivity exists in health systems with cost containment policies
• Biosimilar competition anticipated from other IL-17 inhibitors and biosimilars for older biologics

Future Price Trends

• Likely stabilization or slight decrease due to patent expirations of competitors and biosimilar entries
• Pricing pressure toward $4,500–$5,000 per dose in advanced markets
• Price erosion expected at 2-4% annually post-2025 due to biosimilar and generic competition

Patent and Regulatory Landscape

Patent Status

• Eli Lilly holds patents expiring in 2028–2030
• Patent cliffs could trigger biosimilar entries, reducing prices and market share

Regulatory Approvals

• Fast track and priority review designations in multiple markets
• Ongoing expansion into additional indications, including hidradenitis suppurativa

Investment and R&D Outlook

Pipeline

• Investigating ixekizumab in other autoimmune conditions
• Developing biosimilars to extend revenue lifecycle

R&D Challenges

• Competition from emerging biologics targeting IL-23, IL-36 pathways
• Pricing models shifting with market dynamics

Key Takeaways

• TALTZ maintains a strong position in the psoriasis biologics market, with revenue growth driven by expanding indications and geographic reach.
• The market faces increasing pressure from biosimilars, expected to impact prices by 2025 onward, with a potential 2-4% annual erosion.
• Eli Lilly's patent protections currently extend into the late 2020s, but biosimilar competition could accelerate price declines post-patent expiry.
• Growth is forecasted at a compound rate of approximately 7-9%, contingent on market penetration and reimbursement policies.
• Competitive landscape intensifies with newer biologics and therapies in the pipeline, potentially impacting long-term market share.

FAQs

Q1: What are the primary drivers of TALTZ’s revenue growth through 2028?
Expansion into additional indications, increased adoption across global markets, and broadening payer coverage.

Q2: How will biosimilar entry affect TALTZ’s pricing?
Biosimilars are expected to enter around 2025–2026, likely leading to a 15-30% price reduction depending on market and patent status.

Q3: What are the risks to TALTZ’s market share?
Emergence of novel biologics targeting alternative pathways, biosimilar competition, and changes in reimbursement policies.

Q4: How does TALTZ compare to its competitors in market penetration?
It holds ~15-20%, trailing Cosentyx (~35-40%) but ahead of Siliq (~10-15%) as of 2022.

Q5: What is the potential for price erosion due to patent expiration?
Post-2025, prices could decline 2-4% annually amid biosimilar competition, affecting revenue projections.

References

1. IQVIA. "Global Psoriasis Market Report," 2022.
2. Eli Lilly. "TALTZ Product Details."
3. MarketWatch. "Biologics Price Trends," 2022.
4. FDA. "TALTZ Approval Summary," 2016.
5. EvaluatePharma. "Biologics Market Forecast," 2022.